Annual operating revenue of Jiangsu Hengrui Pharmaceuticals 2022, by market
In 2022, Jiangsu Hengrui Pharmaceuticals generated more than 96 percent of its operating income, or 20.43 billion yuan, from the Chinese market. The company is a market leader in oncology medications in China and was among the